The first coronaviruses that were discovered
to infect humans were known as 229E and OC43, but
they only produced extremely minor infections that were
comparable to the common cold. The potential for
dangerous human infections was not realised until the
epidemics of SARS (severe acute respiratory syndrome)
and then MERS (Middle Eastern Respiratory Syndrome
or camel flu). It is believed that those two illnesses
originated in bats and travelled to civet cats and camels.
The history of publications regarding coronaviruses
shows how interest in them has fluctuated throughout
time. The number of publications on corona-viruses
gradually increased since their discovery in 1968,
reaching two maxima after two epidemics: the SARS
corona-virus outbreak in 2003–2004 and a porcine
epidemic diarrhoea outbreak in North America in 2013.
The discovery of the first cases of MERS in Saudi Arabia
in 2012—a disease similarly brought on by the
coronavirus—may have played a role. While there will
be more than 4 million COVID-19 patients by May 16,
2020, the World Health Organization (WHO) has listed
cancer as one of the top 10 major causes of mortality.
This work deals with 4 different proteins that docked
with various antiviral medicines derived from natural
and synthetic sources, utilising Auto dock Vina 4.2.6.
Molecular docking helps to find compounds such as
antiviral medications with possible inhibitory activity. A
number of studies have demonstrated that the surface
area at the interface directly correlates with binding
affinity and that the hydrophobicity of the interacting
protein molecule increases the selectivity of the binding
Drug Repurposing, Inhibitory Action, Molecular Docking, SARS-COV-2 Nucleocapsid, Htra-Type Protease Algw withTri-Peptide, COVID-19.